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SUMMARY – Gastrointestinal tract is an important connector between food intake and body 
weight, it senses basic tastes in a similar manner as the tongue. The aim of the study was to find out 
how gut hormone glucagon-like peptide-1 (GLP-1) influences taste preference. Fourteen healthy 
participants (six male and eight female) were included in this double-blind, placebo-controlled cross-
over study. After overnight fast and salty fluid (oral sodium load), participants were randomized to 
receive placebo (500 mL of 0.9% saline) or GLP-1 infusion (1.5 pmol/kg/min) over a 3-hour period. 
At the end of infusion, participants chose food preferences from illustrations of food types represent-
ing 5 tastes. After 7 days, the protocol was repeated, this time those that had received placebo first got 
GLP-1 infusion, and those having received GLP-1 first got placebo. Change of taste preference after 
GLP-1 infusion but not after placebo was reported as response, and non-response was reported in case 
of taste persistence. A statistically significant difference in response type was found between genders, 
with women being more likely to change their taste preference after GLP-1 than men. The change of 
taste upon GLP-1 infusion observed in women might be ascribed to estrogen weight-lowering effects 
accomplished by receptor-mediated delivery.
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Introduction
Incretins are substances secreted in the gut after a 
meal. The incretin hormone glucagon-like peptide-1 
(GLP-1) is released from intestinal enteroendocrine L 
cells in response to a carbohydrate meal. GLP-1 has 
many levels of action, but currently it is primarily 
known for its effect on beta cells (the peptide lowers 
blood sugar by stimulating insulin secretion, which 
augments pancreas response within a safe glycemic 
range without inducing hypoglycemia). GLP-1 reduc-
es gastric emptying, lowers appetite by promoting sati-
ety via hypothalamic receptors and reduces food in-
take. As a consequence, GLP-1 action promotes 
weight loss1. GLP-1 receptor agonists are injectable 
hypoglycemic agents, they regulate glucose level and 
promote weight loss. One of these agents, liraglutide, 
is currently indicated at a higher dosage for the treat-
ment of obesity2.
Few clinical studies have demonstrated the impor-
tant association of GLP-1 and different food prefer-
ences in humans. In patients with diabetes type 2, 
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GLP-1 had an effect on appetite via enhanced satiety 
and reduced energy intake3. Intravenous infusions of 
GLP-1 decreased spontaneous food intake in healthy 
non-obese males4. In addition, the process of chewing 
can increase satiety and reduce the decrease in GLP-1 
concentration5, and a relationship was found between 
various styles of mastication and GLP-1 secretion6. 
Data on the effects of GLP-1 on taste preference are 
not available.
To date, there is no specific group of patients iden-
tified as GLP-1 receptor agonist ‘responders’ or ‘non-
responders’ with respect to weight loss. Some patients 
report a diminished craving for food and/or a change 
in food preference with GLP-1 therapy. The hypothe-
sis is that there are some predictors in a group of 
healthy normal weight people that could explain re-
sponsiveness to infusion of native GLP-1 regarding 
different food preference. The aim of this study was to 
investigate whether GLP-1 may influence taste pref-
erence and cause changes in some metabolic parame-
ters.
Subjects and Methods
The study was conducted at the Division of Endo-
crinology, Department of Internal Medicine, Zagreb 
University Hospital Centre. It was approved by the 
Ethics Committee of the Zagreb University Hospital 
Centre and registered at ClinicalTrials.gov Identifier: 
NCT02130778.
Fourteen healthy non obese (body mass index 
(BMI) <30) participants (six male and eight female, 
mean age 37.4 years, range 29-64) were randomized 
for a mechanism based driven, double-blind, placebo-
controlled crossover study. The participants were ran-
domized from the group of healthy volunteers. One 
participant was excluded post-randomization (Fig. 1).
Insulin sensitivity was estimated by simultaneously 
measured fasting plasma glucose (mean fasting glucose 
4.4 mmol/L, range 3.8-5.1) and fasting plasma insulin 
(mean fasting insulin 6.9 mU/L, range 3.3-17) using 
the Homeostasis Model Assessment (HOMA) Cal-
culator (University of Oxford 2013)7. Assessment 
 included HOMA insulin resistance (IR) (mean 
HOMA IR 0.84, range 0.41-2.12), beta cell function 
HOMA2B (mean %B 112.1, range 84.1-191) and in-
sulin sensitivity HOMA2S (mean %S 119.95, range 
47.1-246.2). Baseline GLP-1 was measured in fasting 
state (mean 13.27 pmol/L, range 0-17). Body compo-
sition was estimated using bioelectrical impedance 
analysis (mean fat percentage 19.9%, range 14-32; 
mean fat mass 15.3 kg, range 7.9-20.1; mean muscle 
mass 20.16 kg, range 38.1-77.4; and mean visceral fat 
rating (VFR) 3.92, range 1-7).
Bioimpedance assessment was performed using 
body composition analyzer model TANITA SC-330 
(Tanita Europe B:V: 2004). The BMI of study subjects 
was between 18 and 28 kg/m2. Subjects with BMI 
>25 kg/m2 met the inclusion criterion of normal fat 
percentage; the mean BMI was 23.15 kg/m2 (range 
18.1- 28.4).
Synthetic human GLP-1 was obtained from 
Bachem (Bubendorf, Switzerland). The peptide con-
tent was used in a calculated dosage dissolved in 0.9% 
saline solution. Placebo was 0.9% saline solution. The 
soup used in the trial served as an oral sodium load, 
and its volume was 0.5 L with 12 g NaCl (mean daily 
salt intake in Croatia). The nutrient content of the in-
gested soup included virtually no fat, proteins or sugar, 
with only a small amount of flavor enhancer (monoso-
dium glutamate) and artificial food coloring. The soup 
concentrate was dissolved in standard bottled water. 
The same bottled water brand (natural artesian water, 
calcium/magnesium ratio 2:1, pH 7.4) was served as a 
drink after the soup.
Food map was designed by a registered dietitian. 
The map consists of five pictures. Each picture is a se-
lection of food representing one particular taste (sweet, 
sour, salty, bitter and umami). The selected food has 
one dominant, easily recognizable taste.
Blood for GLP-1 assessment was drawn through 
the antecubital cannula into syringes with EDTA (6 
mol/L) and aprotinin (1000 kIU/L) and kept on ice. 
After centrifugation, plasma samples were kept frozen 
at -20 °C until analysis. GLP-1 was determined by the 
Active GLP-1 (7-36) ELISA ALPCO diagnostic kit.
Standard laboratory methods were used for mea-
surement of laboratory parameters.
Statistical analysis
Data were analyzed using SPSS software (IBM 
SPSS Statistics for Windows, Version 24.0. Armonk, 
NY: IBM Corp.). Descriptive statistics was used to de-
scribe the basic features of the study sample. Since 
Kolmogorov-Smirnov test for normality of distribu-
tion showed some variables deviating significantly 
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from normal distribution, non-parametric indicators 
were also shown as descriptive data. So, for continuous 
variables, mean ± standard deviation, and median and 
interquartile range were used to describe initial data. 
Binary or categorical outcome variables were analyzed 
using χ2-test for comparison of genders in the two 
groups: 2x5 contingency χ2 was used for comparison of 
the choice of food after placebo or GLP-1 infusion, 
and 2x2 contingency χ2 was used for comparison of 
genders according to response to placebo or GLP-1 
infusion. Independent samples t-test was used to com-
pare responders and non-responders according to lab-
oratory and body composition parameters (body fat 
percentage). Since Levene’s test showed a statistically 
significant difference suggesting that variances were 
not homogeneous for some variables, we used the t-
test level of significance when ‘equal variances were 
not assumed’ to compensate for the lack of homogene-
ity. Two-way repeated measures ANOVA was used to 
determine whether the level of insulin changed across 
Fig. 1. Flow diagram of the study.
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the 3 measurement points (baseline, at 3 h and at 6 h 
of starting infusion), using Bonferroni correction for 
multiple comparisons. A significance level of 5% was 
used throughout the analysis. Sample size was not cal-
culated prior to the study. Rather, it was limited due to 
expenses of the study protocol, testing procedures and 
availability of participants since repeated measures 
were required to obtain necessary data. Also, the sam-
ple size corresponded to previous studies performed 
with a similar protocol, which included 12-16 partici-
pants3,4. Post-hoc power analysis using free software 
GPower 3.1 showed very low power of analysis, given 
the sample size n=14, alpha error of probability 0.05, 
and two-way statistical significance (post hoc power 
0.20 for χ2-tests, 0.15 for independent samples t-tests, 
and 0.19 for repeated measures ANOVA)7.
Study protocol
Before being enrolled in the study (screening), the 
participants completed a medical history interview. 
Female participants were not menopausal women; 
they all had regular menstrual cycles and proper meth-
ods of contraception (median age of female partici-
pants was 33 years, range 30-45). None of the partici-
pants reported food neophobia and/or ‘picky/fussy’ 
eating, either currently or in childhood. All partici-
pants had normal glycemia; diabetes was excluded 
based on the standard glucose tolerance test, according 
to the American Diabetes Association guidelines8. 
There were no smokers and currently had no chronic 
diseases. They were instructed to come next day fasting 
for the first visit (Fig. 1).
Randomization was performed by a co-worker not 
included in the study. Eight subjects were randomized 
to receive infusion with GLP-1 first and then placebo; 
another seven subjects were randomized to receive pla-
cebo first and then infusion with GLP-1.
At the first visit, participants signed their informed 
consent. Blood was drawn for laboratory analysis and 
routine physical examination and bioimpedance as-
sessment was performed.
On the second visit day, participants arrived to the 
research unit in the morning after overnight fast. Ini-
tially, oral saline load was delivered in the form of a 
standardized meal (soup). The soup was consumed in 
30 minutes; a sodium-containing meal was used be-
cause it might improve the overall flavor. Participants 
were instructed to drink 1/2 L of bottled water during 
the next 1 hour. In addition to the soup and water, sa-
line infusion with or without GLP-1 (1.5 pmol/kg/
min) was administered at a rate of 0.06 mL/kg/min 
over 3 h from the beginning of oral sodium load. The 
investigators and nurses performing the procedure 
were blinded to the test conditions; the solutions were 
prepared by a technician not involved with study par-
ticipants. Blood samples were obtained at 180 min and 
360 min from the beginning of infusion. At the end of 
the infusion, illustrations of food types were presented 
and the participants were instructed to select the most 
desirable food item. They were instructed to return af-
ter at least 7 days for a third visit, fasting as before. The 
same procedure as on visit 2 was performed on visit 3; 
in one visit they received saline infusion with and in 
another without GLP-1 (1.5 pmol/kg/min).
Results
All 15 participants underwent the same protocol as 
described; one participant randomized to receive infu-
sion with GLP-1 first was excluded due to significant 
age difference, in order to retain group homogeneity 
according to age. This female subject was more than 30 
years older than mean age of others included in the 
study and was excluded due to the fact that taste buds 
diminish as people get older, resulting in declining 
gustatory function, although age was not an exclusion 
criterion.
Seven of the 14 subjects analyzed gave different 
answers to the question: “What would you like most to 
eat right now” after placebo (saline) infusion and after 
GLP-1 infusion. These subjects were considered re-
sponders (with change of taste preference). Among 
responders, the most common taste preference follow-
ing placebo was sweet (3 of 7 responders). Following 
GLP-1 infusion, sweet was again the most prevalent 
taste (3 of 7 responders), although present in those 
participants who had another taste preference follow-
ing placebo. There was no statistically significant dif-
ference between specific taste preference following 
placebo and GLP-1 infusion. In the responder group, 
four subjects received GLP-1 infusion first and three 
subjects received placebo first, suggesting that this or-
der of infusion made no difference. Seven of them gave 
identical answers to the same question after placebo or 
GLP-1 infusion; these participants were considered 
non-responders (without change of taste). Table 1 
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shows characteristics of these two groups. An analysis 
was conducted to compare age, BMI, fat percentage, 
fat and muscle mass, VFR, fasting glucose and glucose 
after 2-hour glucose tolerance test, baseline insulin, 
baseline GLP-1, HOMAB%, HOMA IR and 
HOMA 2S between the two groups. There were no 
statistically significant differences between the groups 
of responders and non-responders in the above mea-
sures (p>0.05 all), except for initial muscle mass, which 
was significantly higher in non-responders than in re-
sponders.
The groups were homogeneous with respect to age, 
anthropometric parameters and baseline metabolic 
laboratory values. The responder group included six fe-
males and one male. The non-responder group in-
cluded five males and two females. A 2x2 contingency 
χ2 table was used for gender comparison in the two 
groups, i.e. yes/no response to placebo/GLP-1 in males 
and females. The χ2-test showed a statistically signifi-
cant gender difference (χ2=4.667, df=1, p=0.031); 
women were more likely to change their taste prefer-
ence after GLP-1 infusion than men.
To compare food preference after placebo in the 
groups of responders and non-responders (i.e. selec-
tion of one of five tastes and yes/no response to place-
bo/vehicle), a 2x5 χ2 table was used. The preference for 
some specific tastes after oral and i.v. sodium loads did 
not differ between responders and non-responders 
(χ2=3.333, df=4, p=0.504). Before GLP-1 infusion, no 
preference for a specific taste existed.
There was no statistically significant difference at 
the 5% level (t=-1.900, df=6.100, p=0.106) in GLP-1 
baseline values between responders and non-respond-
ers. Two-way repeated measures ANOVA was used to 
determine whether the level of insulin changed across 
the 3 measurement points (baseline, after 3 h and 6 h 
of the beginning of infusion). The difference between 
the groups was not statistically significant at the level 
of 5% (F(1,12)=0.155, p>0.05), as so was not the interac-
tion between the groups and the time elapsed from 
infusion (F(1.1,13.6)=0.734, p=0.423). The same analysis 
for GLP-1 levels showed that GLP-1 levels were not 
significantly influenced by the time elapsed from infu-
sion (F(1.1,13.6)=0.500, p=0.518), without difference be-
tween the groups (F(1,12)=3.566, p=0.083), and the in-
teraction between the groups and the time elapsed 
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There was a positive correlation in responders be-
tween the body composition parameter (body fat mass 
in kg) and insulin level 3 h after GLP-1 infusion. 
Spearman’s rank correlation coefficient was r=0.710 
(p<0.010). The higher the body fat mass, the higher 
was insulin response to GLP infusion. We also found a 
strong positive correlation between insulin resistance 
(HOMA IR) and insulin level at 3 h after GLP-1 in-
fusion in responders, r=0.89 (p<0.010) (Fig. 2). The 
higher insulin resistance in responders indicated high-
er insulin response to GLP infusion. A negative cor-
relation was demonstrated for insulin sensitivity 
(HOMA2S) and insulin level r=-0.89 (p<0.010). In 
non-responders, there was no correlation between 
HOMA IR and insulin level at 3 h (r=-0.180).
Discussion
We confirmed the initial hypothesis concerning 
predictors that could explain responsiveness to native 
GLP-1 infusion regarding different food preference. 
The results of this study suggested that women were 
more likely to change their taste preference after 
GLP-1 infusion than men. Why are women more 
prone to taste change after GLP-1 infusion than men?
Difference in sensitivity to central leptin and insu-
lin in male and female rats and the influence of go-
nadal hormones on their central action is well docu-
mented10. Estrogens play an important role in the 
regulation of energy homeostasis. The weight-lowering 
effects of estrogens are associated with decreased food 
intake and increased energy expenditure in experi-
mental animals, modulating energy expenditure and 
feeding behavior through leptin-like effects in the hy-
pothalamus11. Estrogens act directly on brain serotonin 
(5-HT) neurons12. Deletion of the gene encoding es-
trogen receptor α from the entire brain results in obe-
sity due to both hyperphagia and decreased energy 
expenditure13. Estrogen receptors are expressed in 
large quantities in the dorsal raphe nuclei, where most 
5-HT neurons are located14. There is a relationship be-
tween eating disorders and estrogen. Some theories 
claim that estrogens directly act through dorsal raphe 
nuclei 5-HT neurons to inhibit binge eating and that 
impaired brain 5-HT signaling is an important com-
ponent of binge eating development15-18. In humans, 
weight gain during menopause is associated with es-
trogen decline, and such obesity is independent of ag-
ing19. The absence of estrogens has a significant effect 
on obesity in menopausal women20,21. Epidemiologi-
cally, women are approximately three-fold more vul-
nerable than men to psychiatric eating disorders22. Es-
trogens could be a therapeutic option for obesity and 
type 2 diabetes23, but their usage is limited due to their 
female-specific gynecologic action and tumor-pro-
moting properties. There is a potential to develop se-
lective estrogen receptor modulators through tissue-
specific actions. Until now, such a substance was not 
easy to develop due to remaining toxicity concerns and 
mechanistic uncertainties24.
Another option for estrogen delivery is based on a 
peptide carrier that selectively delivers estrogens to 
specific tissues. Improved estrogen action is accom-
plished by GLP-1 receptor-mediated delivery. Central 
stimulation of the GLP-1 receptors reduces feeding 
and food-reward behavior, and this action could be 
Fig. 2. Correlation between insulin resistance (HOMA IR) and insulin level 3 h  
after glucagon-like peptide-1 (GLP-1) infusion in the responder group.
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important for the anorexic actions of estrogens. In ex-
perimental studies, GLP-1-based estrogen conjugates 
were more effective in reducing adiposity and improv-
ing hyperglycemia and dyslipidemia in metabolically 
compromised obese mice than individual agonists 
alone, independent of sex25. In one experimental study, 
the estrogen antagonist was administered centrally 
with GLP-1 receptor agonist exendine 4 to fasting 
male and female rats, and different sensitivities to the 
food reward were noted between female and male rats. 
Female rats exhibited a significant reduction in active 
lever presses and sucrose rewards earned in the non-
food deprived state after exendine 4 treatment. Stimu-
lation with synthetic GLP-1R agonist confirmed dif-
ferent food-motivated behaviors in female rats and 
their interaction with central estrogen signaling26. 
Such data indicate an increased sensitivity to GLP-1 
in females.
Our study results are consistent with previously 
mentioned experimental findings pointing to the fact 
that gender difference in the physiology of eating ex-
ists27. Both groups (responders and non-responders) 
were initially homogeneous, with the exception of ini-
tial muscle mass, which was significantly higher in 
non-responders. This observation could be explained 
by the fact that the non-responder group primarily 
consisted of men27. Both groups were optimally hy-
drated to prevent hunger and thirst responses from be-
ing mistaken for each other.
Exclusively analyzing the responders, a positive 
correlation was noted between body fat percentage and 
insulin level after GLP-1 infusion; a higher body fat 
percentage was associated with higher insulin response 
to GLP-1 infusion. The same correlation was con-
firmed for the VFR, i.e. higher VFR was associated 
with increased insulin response to GLP-1 infusion. 
The strongest positive correlation in responders was 
between insulin resistance HOMA IR and insulin 
level after GLP-1 infusion. Such a correlation was not 
confirmed in the non-responder group. As expected, in 
the responder group, body fat percentage was positive-
ly correlated with insulin resistance. Although no sta-
tistically significant difference in baseline GLP-1 level 
was noted between responders and non-responders, it 
seems that the responders with more symptoms of 
metabolic syndrome (total fat, visceral fat and insulin 
resistance) react with higher insulin after GLP-1 infu-
sion.
To our knowledge, this is the first study exploring 
sex differences in response to GLP-1 infusion. A study 
limitation was the number of participants (although 
similar studies assessing GLP-1 involved 15-16 par-
ticipants). The sample size did not exclude inter- and 
intra-individual variability.
In conclusion, we found healthy non-obese females 
to respond differently to GLP-1 infusion than males. 
Females had a tendency to change their taste prefer-
ences following increase in GLP-1 plasma levels. The 
observed results may be attributable to the effect of 
estrogen in females and the improved central action 
accomplished by GLP-1 receptor-mediated delivery. 
Sex differences in the physiology of eating and re-
sponse to GLP-1 stimuli may contribute to better un-
derstanding of human obesity and eating disorders.
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Sažetak
GLUKAGONU SLIČAN PEPTID-1 RAZLIČITO UTJEČE NA PERCEPCIJU OKUSA U ŽENA:  
RANDOMIZIRANA, PLACEBOM KONTROLIRANA UKRIŽENA STUDIJA
M. Baretić, V. Kušec, V. Uroić, I. Pavlić-Renar i V. Altabas
Probavni sustav povezuje unos hrane i tjelesnu masu razlikujući osnovne okuse sličnim mehanizmima kao i jezik. Cilj ove 
studije bio je istražiti kako glukagonu sličan peptid-1 (GLP-1) utječe na sklonost određenom okusu. Četrnaestoro zdravih 
ispitanika (šest muškaraca i osam žena) uključeno je u randomiziranu, placebom kontroliranu ukriženu studiju. Ispitanicima 
koji su bili natašte dana je slana tekućina (oralno opterećenje solju), nakon čega su randomizirani za placebo (500 mL 0.9% 
fiziološke otopine) ili infuziju GLP-1 (1.5 pmol/kg/min) tijekom 3 sata. Na kraju infuzije ispitanicama su predočene slike 
hrane koje predstavljaju 5 osnovnih okusa pa su birali okus kojem su najviše skloni. Nakon 7 dana postupak se ponovio; 
onima kojima je prvi puta dan placebo primijenjen je GLP-1, a onima koji su prvi put dobili GLP-1 primijenjen je placebo. 
Promjena sklonosti određenom okusu nakon infuzije GLP-1, no ne i nakon placeba, smatrala se pozitivnim odgovorom, a 
negativan je bila nepromijenjena sklonost okusu. Analizirajući ispitanike prema spolu nađeno je da žene imaju veću vjerojat-
nost promjene sklonosti okusa nakon GLP-1 nego muškarci, što je bilo statistički značajno. Navedeno opažanje promjeni 
okusa nakon infuzije GLP-1 u ispitanica može se objasniti učinkom estrogena na gubitak tjelesne mase koji se objašnjava 
receptorski posredovnim prijenosom.
Ključne riječi: Glukagonu sličan peptid 1; Okus; Hrana, preferencije; Ukriženo istraživanje; Dvostruko-slijepa metoda
